問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

List

85Cases

2015-07-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-08-24 - 2019-09-30

Phase III

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

  • Condition/Disease

    Small-Cell Lung Cancer (SCLC)

  • Test Drug

    Durvalumab; Tremelimumab

Participate Sites
11Sites

Terminated10Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏德椿
China Medical University Hospital-Taipei

未分科

2018-02-01 - 2021-06-30

Phase III

A multicenter, randomized, double-blind, placebo-controlled, parallel-grouped Phase III trial to evaluate the efficacy and safety of Tezepelumab in adults and adolescents with poorly controlled severe asthma

  • Condition/Disease

    As an additional maintenance treatment for patients over 12 years old with severe asthma

  • Test Drug

    Tezepelumab

Participate Sites
4Sites

Terminated4Sites

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

  • Condition/Disease

    Severe eosinophilic leukocyte asthma

  • Test Drug

    Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬
Taipei Medical University Hospital

Division of Thoracic Medicine

2019-08-01 - 2022-12-31

Phase III

A Multicentre, Double-blind, Randomized, Parallel Group, Placebo Controlled, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (Destination)

  • Condition/Disease

    Severe Uncontrolled Asthma (12 years of age and older)

  • Test Drug

    Tezepelumab

Participate Sites
3Sites

Recruiting3Sites

2021-08-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2017-02-06 - 2018-12-31

IIT

Phase IV

The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acteylcysteine (NAC)

  • Condition/Disease

    Tuberculosis

  • Test Drug

    Actein

Participate Sites
4Sites

Recruiting4Sites

2019-04-01 - 2022-05-31

Phase III

A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

  • Condition/Disease

    idiopathic pulmonary fibrosis

  • Test Drug

    GLPG1690 (G451990)

Participate Sites
5Sites

Recruiting4Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2021-02-01 - 2022-06-16

Phase III

ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Condition/Disease

    Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Test Drug

    Amikacin liposome inhalation suspension (ALIS)

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2018-05-01 - 2023-09-30

Phase III

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

  • Condition/Disease

    TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer

  • Test Drug

    Keytruda injection

Participate Sites
15Sites

Recruiting1Sites

Terminated13Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB